$8.07
1.38%
Nasdaq, Oct 05, 04:13 pm EDT. Closed.
ISIN
US4525EP1011
Symbol
IMUX

Immunic, Inc. Target price 2026 - Analyst rating & recommendation

Immunic, Inc. Classifications & Recommendation

Buy
94%
Hold
6%

Immunic, Inc. Price Target

Target Price $30.60
Price $8.07
Potential
Number of Estimates 13
13 Analysts have issued a price target Immunic, Inc. 2027 . The average Immunic, Inc. target price is $30.60. This is higher than the current stock price. The highest price target is
$89.25 1,005.95%
register free of charge
, the lowest is .
A rating was issued by 18 analysts: 17 Analysts recommend Immunic, Inc. to buy, 1 to hold and 0 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the Immunic, Inc. stock has an average upside potential 2027 of . Most analysts recommend the Immunic, Inc. stock at Purchase.

Earnings per share, P/E ratio and EV/sales Estimates 2026, 2027 to 2033

Create a premium account to unlock analyst estimates. Learn more

Select at least one metric to display the chart.


Dec '25 2026
Estimates
Earnings Per Share $ -6.24 -3.67
37.79% 41.19%
P/E negative

13 Analysts have issued a Immunic, Inc. forecast for earnings per share. The average Immunic, Inc. EPS is

$-3.67
unlock
. This is
40.08% lower
unlock
than earnings per share in the financial year 2025. The highest EPS forecast is
$-3.24 23.66%
unlock
, the lowest is
$-5.61 114.12%
unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2025 $-6.24 37.79%
2026
$-3.67 41.19%
unlock
2027
$-2.49 32.15%
unlock
2028
$-2.52 1.20%
unlock
2029
$-0.64 74.60%
unlock
2030
$2.24 450.00%
unlock
2031
$4.23 88.84%
unlock
2032
$6.66 57.45%
unlock
2033
$9.21 38.29%
unlock

P/E ratio

Current -3.04 149.11%
2026
-2.17 28.58%
unlock
2027
-3.20 47.47%
unlock
2028
-3.16 1.25%
unlock
2029
-12.35 290.82%
unlock
2030
3.56 128.83%
unlock
2031
1.88 47.19%
unlock
2032
1.20 36.17%
unlock
2033
0.86 28.33%
unlock

Current Immunic, Inc. Upgrades & Downgrades

Create a Premium account to unlock Upgrades/Downgrades. Learn more
Analyst Rating Action Date
Wedbush
Locked
➜
Locked
Locked Sep 10 2026
HC Wainwright & Co.
Locked
➜
Locked
Locked Sep 10 2026
Wedbush
Locked
➜
Locked
Locked Aug 17 2026
B. Riley Securities
Locked
➜
Locked
Locked May 22 2026
HC Wainwright & Co.
Locked
➜
Locked
Locked Apr 30 2026
Stifel
Locked
➜
Locked
Locked Apr 17 2026
D. Boral Capital
Locked
➜
Locked
Locked Apr 15 2026
Analyst Rating Date
Locked
Wedbush:
Locked
➜
Locked
Sep 10 2026
Locked
HC Wainwright & Co.:
Locked
➜
Locked
Sep 10 2026
Locked
Wedbush:
Locked
➜
Locked
Aug 17 2026
Locked
B. Riley Securities:
Locked
➜
Locked
May 22 2026
Locked
HC Wainwright & Co.:
Locked
➜
Locked
Apr 30 2026
Locked
Stifel:
Locked
➜
Locked
Apr 17 2026
Locked
D. Boral Capital:
Locked
➜
Locked
Apr 15 2026

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today